Menotropins - Biologic Drug Details

Summary for menotropins

Tradenames:	4
High Confidence Patents:	2
Applicants:	3
BLAs:	4
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for menotropins

Recent Clinical Trials for menotropins

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Kuban State Medical University	Phase 2
Assiut University	N/A
Ferring Pharmaceuticals	Phase 3

See all menotropins clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for menotropins Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for menotropins Derived from Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Ferring Pharmaceuticals Inc.	MENOPUR	menotropins	For Injection	021663	5,618,913	2014-04-08	Company disclosures
Ferring Pharmaceuticals Inc.	MENOPUR	menotropins	For Injection	021663	5,866,538	2016-06-20	Company disclosures

3) Low Certainty: US Patents for menotropins Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Emd Serono, Inc.	PERGONAL	menotropins	For Injection	017646	10,016,338	2033-03-11	Patent claims search
Emd Serono, Inc.	PERGONAL	menotropins	For Injection	017646	10,577,154	2029-05-13	Patent claims search
Emd Serono, Inc.	PERGONAL	menotropins	For Injection	017646	10,656,152	2029-01-29	Patent claims search
Emd Serono, Inc.	PERGONAL	menotropins	For Injection	017646	10,695,289	2035-10-09	Patent claims search
Emd Serono, Inc.	PERGONAL	menotropins	For Injection	017646	10,912,714	2038-07-09	Patent claims search

International Patents for menotropins

Country	Patent Number	Estimated Expiration
Norway	985981
China	1029977
Germany	3650101
Israel	79887
Japan	2009235075

Supplementary Protection Certificates for menotropins

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
SPC/GB99/045	United Kingdom		SPC/GB99/045: 20060829, EXPIRES: 20110828
99C0044	Belgium		PRODUCT NAME: INSULIN-ASPART; NAT. REGISTRATION NO/DATE: EU/1/99/119/001 19990907; FIRST REGISTRATION: CH 55045 01 19990615
SZ 50/1999	Austria		PRODUCT NAME: INSULIN ASPART
C00214826/01	Switzerland		FORMER REPRESENTATIVE: E. BLUM AND CO. PATENTANWAELTE, CH
C990042	Netherlands		PRODUCT NAME: INSULIN ASPART; REGISTRATION NO/DATE: EU/1/99/119/001 - EU/1/99/119/005 19990907

Menotropins Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Menotropins

Introduction to Menotropins

Menotropins, a type of biologic drug, are used in the treatment of infertility in both men and women. These drugs are derived from human menopausal gonadotropin (hMG) and play a crucial role in stimulating follicle development in women and spermatogenesis in men.

Global Market Size and Growth

The global menotropin market is experiencing significant growth driven by several key factors. As of 2024, the market size is estimated to be USD xx million, with a projected compound annual growth rate (CAGR) of 6.00% from 2024 to 2031, reaching USD XX million by 2031[1].

Drivers of Market Growth

Increasing Infertility Rates

One of the primary drivers of the menotropin market is the increasing rate of infertility globally. Factors such as delayed childbearing, lifestyle changes, environmental factors, and underlying health conditions contribute to rising infertility rates. This trend translates into a growing demand for assisted reproductive technologies (ART), including menotropin treatments[1][4].

Advancements in Assisted Reproductive Technologies (ART)

Advancements in ART have significantly improved the success rates of fertility treatments. Menotropin plays a crucial role in these technologies by stimulating follicle development and spermatogenesis, making it an essential component of modern fertility treatments[1].

Rising Awareness and Acceptance

There is a growing awareness and acceptance of fertility treatments among the general population. This shift, coupled with supportive regulatory frameworks and increasing healthcare expenditure, further propels the market growth[1].

Technological Innovations

Technological innovations in fertility treatments are enhancing treatment efficacy and patient outcomes. Personalized medicine approaches and other technological advancements are key trends in the menotropin market, contributing to its growth[1].

Regional Market Dynamics

North America

North America holds a significant share of the global menotropin market, accounting for more than 40% of the global revenue in 2024. The region is expected to grow at a CAGR of 2.7% from 2024 to 2031[1].

Europe

Europe also has a substantial market share, with over 30% of the global revenue in 2024. The European market is projected to grow at a CAGR of 4.5% from 2024 to 2031[1].

Asia Pacific

The Asia Pacific region is experiencing the fastest growth in the menotropin market, driven by rising infertility rates, increasing adoption of advanced fertility treatments, and improving healthcare infrastructure. Countries like China and India are key contributors to this growth, with the region expected to grow at a CAGR of 8.0% from 2024 to 2031[1].

Latin America and Middle East & Africa

Latin America and the Middle East & Africa also show promising growth, with CAGRs of 5.4% and 5.7%, respectively, from 2024 to 2031. These regions are driven by increasing healthcare expenditure and growing awareness about reproductive health[1].

Market Challenges

High Cost of Treatment

One of the significant challenges facing the menotropin market is the high cost of treatment. The mean cost per patient treatment cycle can range from £2,423 to £2,745, depending on the type of gonadotropin used[5].

Regulatory Complexities

Regulatory complexities and ethical considerations also pose challenges to the market. Navigating these complexities is crucial for sustaining growth in the menotropin market[1].

Key Players and Market Share

The menotropin market is dominated by a few key players. Drugs like Menopur (menotropins) by Ferring Pharmaceuticals, Gonal-F (follitropin alfa) by EMD Serono, and Follistim (follitropin beta) by Merck hold over 50% of the market share. These drugs are widely used in fertility treatments and continue to drive market growth[2].

Financial Implications

Cost-Effectiveness

Highly purified hMG (menotropin) is often more cost-effective compared to recombinant FSH. Using highly purified hMG can result in a 13% increase in the number of treatment cycles that can be offered, making it a financially viable option for many patients[5].

Market Value

The global female infertility pharmaceutical market, which includes menotropins, is expected to grow significantly. For instance, the female infertility drug market was valued at $1.8 billion in 2018 and is projected to reach $2.5 billion by the end of the forecast period, growing at a CAGR of 3.4% from 2018 to 2028[2].

Technological and Regulatory Trends

Biosimilars and Generics

The biologics market, including menotropins, is beginning to face competition from biosimilars. By the end of 2019, 17% of the biologics market was accessible to biosimilars, and this trend is expected to continue, potentially impacting the market dynamics of menotropins[3].

Personalized Medicine

The adoption of personalized medicine approaches in fertility treatments is a key trend. This involves tailoring treatments to individual patient needs, which can enhance treatment efficacy and patient outcomes[1].

Conclusion

The menotropin market is poised for significant growth driven by increasing infertility rates, advancements in ART, and technological innovations. Despite challenges such as high treatment costs and regulatory complexities, the market is expected to expand substantially over the next few years.

Key Takeaways

• The global menotropin market is projected to grow at a CAGR of 6.00% from 2024 to 2031.
• Increasing infertility rates and advancements in ART are key drivers of market growth.
• The Asia Pacific region is experiencing the fastest growth due to rising infertility rates and improving healthcare infrastructure.
• High treatment costs and regulatory complexities are significant challenges.
• Key players like Ferring Pharmaceuticals, EMD Serono, and Merck dominate the market.
• The adoption of personalized medicine and technological innovations are crucial trends.

FAQs

What are the primary drivers of the menotropin market?

The primary drivers include increasing infertility rates globally, advancements in Assisted Reproductive Technologies (ART), and rising awareness and acceptance of fertility treatments.

Which region is experiencing the fastest growth in the menotropin market?

The Asia Pacific region is experiencing the fastest growth, driven by rising infertility rates, increasing adoption of advanced fertility treatments, and improving healthcare infrastructure.

What are the challenges facing the menotropin market?

The high cost of treatment, regulatory complexities, and ethical considerations are significant challenges.

Who are the key players in the menotropin market?

Key players include Ferring Pharmaceuticals, EMD Serono, and Merck, with drugs like Menopur, Gonal-F, and Follistim dominating the market.

How is the adoption of personalized medicine impacting the menotropin market?

The adoption of personalized medicine approaches is enhancing treatment efficacy and patient outcomes, contributing to the growth of the menotropin market.

Sources

1. Cognitive Market Research: Global Menotropin Market Report 2024.
2. European Pharmaceutical Review: Female infertility drug market to exhibit CAGR of 3.4 percent.
3. FTC: Biologics Market Dynamics: Setting the Stage for Biosimilars.
4. The Insight Partners: Menotropin Market Strategies and Share 2031.
5. PubMed: Economic evaluation of highly purified menotropin compared with recombinant FSH.